{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:06Z","timestamp":1793214606004,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>There is a growing array of options for the treatment of immune-mediated inflammatory diseases (IMIDs). To explore upadacitinib\u2019s efficacy and safety in autoimmune disease treatment, we conducted this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pubmed, Web of Science and Embase were searched for randomized controlled trials related to the treatment of upadacitinib from the databases\u2019 inception to May 31, 2024. After literature screening, data extraction and bias assessment by two investigators, RevMan 5.3 or Stata 17.0 software was used for meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>45 records across the following five types of IMIDs were obtained. For rheumatoid arthritis (RA), upadacitinib 15 mg outperformed placebo, methotrexate and adalimumab (ADA) in 20% improvement according to ACR criteria (ACR20) and 28-joint disease activity score (DAS28) (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). It also improved quality of daily life based on pain relief, morning stiffness and 36-Item Short Form Health Survey, etc. For axial spondyloarthritis (axSpA), upadacitinib 15 mg enhanced 20\/40% improvement in Assessment of SpondyloArthritis international Society (Risk Ratio [RR] = 1.28\/1.47), with better rates of low disease activity and inactive disease as well. For psoriatic arthritis (PsA), upadacitinib 15 mg or 30 mg significantly improved ACR20 compared to placebo (RR = 2.46\/2.68, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and reduced psoriasis skin lesions, though it showed no superior benefit for enthesitis compared to placebo. For Crohn\u2019s disease (CD), upadacitinib 45 mg significantly improved stool frequency and abdominal pain score clinical remission compared to placebo (RR = 2.47, 95% CI [2.12, 2.88], <jats:italic>P<\/jats:italic> &amp;lt; 0.001) as well as Crohn\u2019s Disease Activity Index score remission and endoscopic response (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). For ulcerative colitis (UC), upadacitinib 45 mg increased clinical remission rates (RR = 6.92, 95% CI [4.99, 9.59], <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and improved symptoms like bowel frequency and abdominal pain (<jats:italic>P<\/jats:italic> &amp;lt; 0.05). Overall adverse events (AEs) rates were generally similar to non-upadacitinib groups (RR = 1.02, 95% CI [0.98, 1.07]). However, the higher risks of infections especially herpes zoster (HZ) must be highlighted in upadacitinib group. Although the incidence of death, serious adverse events (SAEs), and long-term risks like cardiovascular events and malignancies were without statistic significant differences, careful monitoring during treatment would still be essential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Upadacitinib is effective in treating IMIDs like RA, axSpA, PsA, CD, and UC. Though well-tolerated generally, its safety in infection especially HZ needs caution. Thorough assessment, monitoring and individualized dosing are vital to manage potential AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024569370.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1586792","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:50Z","timestamp":1751347730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Rui","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genhong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020100","article-title":"The effect of infections on susceptibility to autoimmune and allergic diseases","volume":"347","author":"Bach","year":"2002","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0140-6736(18)32763-6","article-title":"Baricitinib for systemic lupus erythematosus","volume":"393","author":"Yuan","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222053","article-title":"Pilot study of baricitinib for active Sjogren\u2019s syndrome","volume":"81","author":"Bai","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12305","article-title":"Landscape of new drugs and targets in inflammatory bowel disease","volume":"10","author":"Vieujean","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13750-022-00264-0","article-title":"Principles and framework for assessing the risk of bias for studies included in comparative quantitative environmental systematic reviews","volume":"11","author":"Frampton","year":"2022","journal-title":"Environ Evid"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat In Med"},{"key":"B13","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"Higgins","year":"2021"},{"key":"B14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13075-023-03128-1","article-title":"Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-022-02813-x","article-title":"Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15\u2013000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-1062","article-title":"Upadacitinib in rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: efficacy and safety through 5 years (SELECT-NEXT)","volume":"51","author":"Burmester","year":"2024","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"9","author":"Burmester","year":"2022","journal-title":"Rheumatol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00624-3","article-title":"Impact of upadacitinib on laboratory parameters and related adverse events in patients with RA: integrated data up to 6.5 years","volume":"11","author":"Charles-Schoeman","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces crohn\u2019s disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40744-021-00399-5","article-title":"Benefit-risk analysis of upadacitinib compared with adalimumab in the treatment of patients with moderate-to-severe rheumatoid arthritis","volume":"9","author":"Conaghan","year":"2022","journal-title":"Rheumatol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad017","article-title":"Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials","volume":"7","author":"Conaghan","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad016","article-title":"Upadacitinib induction and maintenance therapy improves abdominal pain, bowel urgency, and fatigue in patients with ulcerative colitis: A post hoc analysis of phase 3 data","volume":"29","author":"Danese","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between janus kinase inhibitor upadacitinib and adalimumab following insufficient response: Efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84\u2009weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): A placebo-controlled phase IIb\/III study","volume":"59","author":"Kameda","year":"2020","journal-title":"Rheumatol (United Kingdom)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"New Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-psA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002049","article-title":"Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-psA 2 study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac477","article-title":"Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE","volume":"62","author":"Mysler","year":"2023","journal-title":"Rheumatology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab905","article-title":"Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis","volume":"61","author":"Nash","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac260","article-title":"Induction and maintenance treatment with upadacitinib improves health-related quality of life in patients with moderately to severely active ulcerative colitis: phase 3 study results","volume":"29","author":"Pan\u00e9s","year":"2023","journal-title":"Inflammatory Bowel Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-7-5","article-title":"Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: A subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients","volume":"9","author":"Pavelka","year":"2020","journal-title":"Drugs Context"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab861","article-title":"Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program","volume":"61","author":"Peterfy","year":"2022","journal-title":"Rheumatol (United Kingdom)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01660-7","article-title":"Quality of life and work productivity improvements with upadacitinib: phase 2b evidence from patients with moderate to severe crohn\u2019s disease","volume":"38","author":"Peyrin-Biroulet","year":"2021","journal-title":"Adv Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.026","article-title":"Upadacitinib achieves clinical and endoscopic outcomes in crohn\u2019s disease regardless of prior biologic exposure","volume":"22","author":"Peyrin-Biroulet","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-psA 1","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatol Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-019-2037-1","article-title":"Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: Results from SELECT-NEXT","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13075-019-2059-8","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab158","article-title":"Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: Results from SELECT-COMPARE","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatol (United Kingdom)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa770","article-title":"Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: Results from SELECT-EARLY and SELECT-MONOTHERAPY","volume":"60","author":"Strand","year":"2021","journal-title":"Rheumatol (United Kingdom)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11669","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, phase 3 trial","volume":"6","author":"Van den Bosch","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"Van Der Heijde","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"Van Der Heijde","year":"2022","journal-title":"RMD Open"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14235","article-title":"Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy","volume":"24","author":"Zeng","year":"2021","journal-title":"Int J Rheumatic Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatol (Oxford England)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front In Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11864-020-00815-y","article-title":"Janus kinase inhibitors and non-melanoma skin cancer","volume":"22","author":"Greif","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.7509","article-title":"FRI0131 Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib","volume":"78","author":"Queeney","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1586792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:28:51Z","timestamp":1751347731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1586792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1586792"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1586792","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"1586792"}}